Nutrinia, a Ramat-Gan, Israel-based developer of oral insulin therapies to treat rare gastrointestinal disorders in babies, completed a $12m Series C funding.
The round was led jointly by OrbiMed, Jacobs Investment Company and Pontifax.
The company intends to use the funds to advance two multinational clinical studies to support registration of NTRA-2112 for treating pre-term infants and NTRA-9620 for treating Short Bowel Syndrome in the EU and the United States.
Founded by Professor Naim Shehade, head of pediatrics at the Rambam Medical center in the NGT incubator, Nazareth, Israel, and led by Miki Olshansky, CEO, Nutrinia is developing formulated oral insulin for gut maturation, focusing on dual orphan drug indications – premature infants and short bowel disease.
FinSMEs
19/12/2014